IVERIC BIO, INC.
Presenter SpeechTiago Fauth (Analysts)All right. Welcome, everyone, to the 31st Annual Healthc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
IVERIC bio, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of treatments for retinal diseases with unmet medical needs. Its lead asset is its clinical-stage product candidate, avacincaptad pegol, which is also referred to as ACP or Zimura, a complement C5 inhibitor. Zimura is targeting diseases including geographic atrophy (GA), intermediate age-related macular degeneration (AMD), and autosomal recessive Stargardt disease (STGD1). In addition to ACP, the Company is also developing its preclinical product candidate, IC-500, a high temperature requirement A serine peptidase 1 protein (HtrA1) inhibitor for GA secondary to AMD and potentially other age-related retinal diseases. Its portfolio also includes several ongoing gene therapy research programs, each of which uses adeno-associated virus (AAV) for gene delivery. These AAV mediated gene therapy programs are targeting the orphan inherited retinal diseases (IRDs).
| 1st Jan change | Capi. | |
|---|---|---|
| +22.08% | 44.96B | |
| +0.86% | 42.65B | |
| +46.00% | 41.85B | |
| -4.27% | 29.04B | |
| +10.51% | 26.08B | |
| -20.86% | 19.03B | |
| +5.52% | 12.75B | |
| +27.94% | 12.06B | |
| -3.83% | 11.75B |
